Inactive Instrument

News QUANTUM GENOMICS Euronext Paris

Equities

FR0011648971

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-

Mar. 13	Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quantum Genomics : Quantum Genomics announces that it has obtained the approval of Shareholders on the reduction of its share capital and on the contribution in kind of 100% of ExactCure’s securities.	Apr. 25	AT
Quantum Genomics : Quantum Genomics publishes its results for the 2023 financial year. The merger with ExactCure, which marks the strategic redeployment of the company and will be submiCed for a shareholder vote on April 24.	Mar. 13	AT
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Quantum Genomics : Quantum Genomics enters into exclusive negotiations with ExactCure	Dec. 14	AT
Quantum Genomics : Quantum Genomics Releases First-Half 2023 Financial Results	23-10-24	AT
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-24	CI
Quantum Genomics: negotiations with Vistacare terminated	23-10-18	CF
Quantum Genomics : Quantum Genomics announces resuming discussions with HealthTech companies following the termination of exclusive negotiations with Vistacare Medical	23-10-17	AT
Quantum Genomics : Quantum Genomics enters into exclusive negotiations with Vistacare Medical with the ambition of creating a reference player in the management of complex wounds	23-07-20	AT
Global markets live: Microsoft, Raytheon, JPMorgan, Credit Suisse...	23-05-26
Quantum Genomics : Quantum Genomics releases its 2022 financial results and provides an update on its MandA discussions	23-05-26	AT
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-26	CI
Quantum Genomics: advanced discussions with a partner	23-04-06	CF
Quantum Genomics Ousts Board President; CEO Named Successor	23-02-23	MT
Quantum Genomics : Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects	23-02-22	AT
Quantum Genomics : Quantum Genomics gives an update	22-12-08	AT
Quantum Genomics' Hypertension Drug Firibastat Fails to Show Significant Efficacy in Late-Stage Trial	22-10-28	MT
Quantum Genomics : Quantum Genomics announces lack of significant efficacy for firibastat in their phase III study, FRESH and is redirecting to new developments	22-10-28	AT
Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments	22-10-28	AQ
Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments	22-10-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News QUANTUM GENOMICS Euronext Paris

Equities

FR0011648971

Summary

Filters